Conference
Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure
Abstract
Abstract
BACKGROUND: Allogeneic hematopietic cell transplantation (HCT) is still an important option of treatment in CML patients failing respond to tyrosine kinase inhibitors (TKIs). The revised European LeukemiaNet 2013 suggests HCT to be reserved for the patients in chronic phase (CP) unless resistant or intolerant to at least one second-generation TKI. The present retrospective study attempted to evaluate transplant …
Authors
Kim DDH; Bence-Bruckler I; Hillis CM; Walker I; Kamel-Reid S; Lipton JH
Volume
124
Publisher
American Society of Hematology
Publication Date
December 6, 2014
DOI
10.1182/blood.v124.21.4554.4554
Conference proceedings
Blood
Issue
21
ISSN
0006-4971